Pfizer eyes emerging market push

Jean-Michel Halfon, Pfizer's head of emerging markets has announced plans for a big push into the world's underdeveloped emerging markets, Reuters has reported. Almost 75% of pharmaceutical sales growth will come from emerging markets in the next three to five years, he said, adding that Saudi Arabia, Thailand and Taiwan are "promising areas of interest" for the world's largest pharmaceutical company. Pfizer had Q3 sales from emerging markets of about $1.6bn, which represented growth of 9%. Including revenue from recently acquired Wyeth, that quarterly figure would have been between $2bn and $2.1bn, Halfon said.